February 18, 2016
Patients who battle both hepatitis C and a health plan that denies coverage for the cure have a new recourse: legal action.
February 16, 2016
The Food and Drug Administration could soon approve a complex biosimilar to treat eight disease states and patient groups – even though clinical testing data has been submitted for only two.
February 16, 2016
For most of history, hepatitis C has been incurable after the development of chronic infection.
February 9, 2016
President Barack Obama’s 2017 fiscal year budget reflects the White House’s growing concerns about the abuse and misuse of opioids.
February 9, 2016
Patients with chronic or serious medical conditions must sometimes work with physicians for months to identify a medication that’s effective for them. But as a new video from the Alliance for Patient Access explains, patients may discover that this trial-and-error process was in vain.
February 8, 2016
The Centers for Medicare and Medicaid Services’ billing code system for biosimilars earned it a “D-” grade at the House Energy and Commerce Health Subcommittee’s February 4 hearing on biologics.
February 4, 2016
In a November 2015 notice the Centers for Medicare and Medicaid Services warned that states rationing costly hepatitis C cures may “unreasonably restrict access” for Medicaid patients.
February 2, 2016
A tool designed to deliver cost-effective, quality cancer care needs reform, announced the American Society of Clinical Oncology (ASCO) in a January policy statement.
January 28, 2016
After years of international debate, the World Health Organization has issued its final proposal embracing distinct names for biological medicines, including biosimilars.
January 28, 2016
January 26 ended the public comment period for the U.S. Senate Finance Committee’s chronic care working group policy options paper—cueing the group’s legislative efforts to begin in earnest.
